


## Author's Accepted Manuscript

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschhof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J. Lackner, Leszek Wojnowski, Serge P. Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel, Andreas Daiber



PII: S2213-2317(17)30393-2  
DOI: <http://dx.doi.org/10.1016/j.redox.2017.06.009>  
Reference: REDOX701

To appear in: *Redox Biology*

Received date: 29 May 2017  
Revised date: 20 June 2017  
Accepted date: 21 June 2017

Cite this article as: Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschhof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J. Lackner, Leszek Wojnowski, Serge P. Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel and Andreas Daiber, The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats, *Redox Biology*, <http://dx.doi.org/10.1016/j.redox.2017.06.009>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats**

Sebastian Steven<sup>a,b1</sup>, Matthias Oelze<sup>a1</sup>, Alina Hanf<sup>a1</sup>, Swenja Kröller-Schön<sup>a</sup>, Fatemeh Kashani<sup>a</sup>, Siyer Roohani<sup>a</sup>, Philipp Welschof<sup>a</sup>, Maximilian Kopp<sup>a</sup>, Ute Gödtel-Armbrust<sup>c</sup>, Ning Xia<sup>d</sup>, Huige Li<sup>d,g</sup>, Eberhard Schulz<sup>a</sup>, Karl J. Lackner<sup>e</sup>, Leszek Wojnowski<sup>c</sup>, Serge P. Bottari<sup>f</sup>, Philip Wenzel<sup>a,b,g</sup>, Eric Mayoux<sup>h</sup>, Thomas Münzel<sup>a,g</sup>, and Andreas Daiber<sup>a,g\*</sup>

<sup>a</sup>Center for Cardiology, Cardiology I – Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany

<sup>b</sup>Center for Thrombosis and Hemostasis, Medical Center of the Johannes Gutenberg University, Mainz, Germany, Medical Center of the Johannes Gutenberg University, Mainz, Germany

<sup>c</sup>Department of Toxicology, Medical Center of the Johannes Gutenberg University, Mainz, Germany

<sup>d</sup>Department of Pharmacology, Medical Center of the Johannes Gutenberg University, Mainz, Germany

<sup>e</sup>Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany

<sup>f</sup>Institute for Advanced Biosciences, INSERM U1209 – CNRS UMR 5309, Grenoble-Alps University and Institute for Biology and Pathology, CHU, Grenoble, France

<sup>g</sup>German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany

<sup>h</sup>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

---

<sup>1</sup> S.S., M.O. and A.H. contributed equally to this study and should therefore all be considered as first author.

Download English Version:

<https://daneshyari.com/en/article/8286864>

Download Persian Version:

<https://daneshyari.com/article/8286864>

[Daneshyari.com](https://daneshyari.com)